Galapagos Boasts ''Best-In-Class'' With Its RA JAK Inhibitor
This article was originally published in Scrip
Galapagos NV has thrown down the gauntlet to its rivals in the JAK inhibitor space, saying new Phase II data support a potential "best-in-class" title for its drug candidate filgotinib in rheumatoid arthritis. AbbVie Inc. now has 60 days to decide whether it wants to take up its option to license the product, something which analysts say these data make almost inevitable.
You may also be interested in...
The US FDA has given the go-ahead for marketing of ViiV healthcare’s novel HIV drug just as the EMA removes the accelerated assessment status from its application there.
Executives On The Move: BioXcel Therapeutics Picks A Development Officer, A Finance Hire At RenovaCare And CANbridge Taps Takeda Talent
Immuno-oncology and neuroscience firm BioXcel Therapeutics picks a chief development officer, and stem-cell therapy company RenovaCare hires a CFO. Plus, CANbridge Life Sciences, developer of specialty health products, adds Takeda Pharma rare disease lead as global head, business development.
Topline Phase II data for the antibody-drug conjugate tisotumab vedotin put it on a swift path towards approval in cervical cancer.